Abstract A17: Probing a translational switch involved in tumor angiogenesis

Abstracts: AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; October 27-30, 2016; San Francisco, CA As a tumor proliferates, it rapidly outgrows its blood supply, creating an oxygen-starved environment. Low oxygenation (hypoxia) suppresses the canonical biochemical pathway through which the translation of messenger RNAs (mRNAs) into proteins by the ribosome is typically initiated. Despite shutting down this general mechanism for initiating protein synthesis, the tumor can continue to initiate translation of a subset of mRNAs that are involved in angiogenesis and tumor survival. To explain this observation, it has been proposed that, in addition to the eukaryotic mRNA-specific 7-methyl guanosine cap at the 5' end, these pro-angiogenic mRNAs, of which Fibroblast Growth Factor-9 (FGF9) and Hypoxia Inducible Factor 1α (HIF1α) are prototypical members, contain highly stable structures in their 5' untranslated regions. These structures, also referred to as Cap Independent Translation Enhancers (CITEs), form part of a switch that activates a non-canonical pathway for initiating translation, presumably by binding directly to eukaryotic initiation factor 4G (eIF4G), thereby recruiting ribosomes in a manner distinct from the canonical 5' cap-dependent mechanism. To test this hypothesis, here we report the binding affinities of pro-angiogenic mRNAs, as well as control mRNAs lacking CITEs, to eIF4G as a measure of their ability to initiate translation in the hypoxic environment of a tumor. Understanding the dynamics of eIF4G-CITE interactions can inform the design and development of novel angiogenesis inhibitors that function by targeting these interactions. Citation Format: Maya Ramachandran, Somdeb Mitra, Ruben L. Gonzalez, Jr. Probing a translational switch involved in tumor angiogenesis. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr A17.